DocumentsDate added
0riginal research
Preetinder Singh1,*,Chandni Singla2,Aditi priyamvara2
Affiliation:-
1Assoc. Professor,2Research Associate, Periodontology and Oral Implantology, SDD Hospital and Dental College, Barwala, Haryana, India
The name of the department(s) and institution(s) to which the work should be attributed:
Periodontology and Oral Implantology, SDD Hospital and Dental College, Barwala, Haryana, India
Corresponding author:-
Dr. Preetinder Singh, MDS.
Assoc. Professor (Periodontology and Oral Implantology), SDD Hospital and Dental College, Barwala, Haryana, India
Contact number: +91-9915652946
Abstract: This study was conducted with the aim of evaluation of stress among dental students studying in Chandigarh, India. It identifies the factors responsible for stress among undergraduate dental students. A descriptive quantitative study was conducted using a self-administered questionnaire among Bachelor’s of Dental Surgery students during their preceding academic years. A 100% response from all students was obtained. The final result obtained signifies that the category of somewhat stressful was dominant amongst the total of 4 categories i.e. not stressful at all, somewhat stressful, quite stressful and very stressful. Further research is needed into methods to minimize stress on dental students.
Key words: Dental students; student stress; dentistry.
REFERENCES
1.Humphris G, Blinkhorn A, Freeman R, Gorter R, Hoad-Reddick G, Murtomaa H, et al. Psychological stress in undergraduate dental students: baseline results from seven European dental schools. Eur J Dent Educ 2002; 6(1):22–9.
2.Sugiura G, Shinada K, Kawaguchi Y. Psychological well-being and perceptions of stress amongst Japanese dental students. Eur J Dent Educ 2005; 9(1):17–25.
3.Polychronopoulou A, Divaris K. Perceived sources of stress among Greek dental students. J Dent Educ 2005; 69(6):687–92.
4.Sofola OO, Jeboda SO. Perceived sources of stress in Nigerian dental students. Eur J Dent Educ 2006;10(1):20–3.
5.Morse Z, Dravo U. Stress levels of dental students at the Fiji School of Medicine. Eur J Dent Educ 2007; 11(2):99–103.
6.Muirhead V, Locker D. Canadian dental students’ perceptions of stress. J Can Dent Assoc 2007; 73(4):323.
7.Gorter R, Freeman R, Hammen S, Murtomaa H, Blinkhorn A, Humphris G. Psychological stress and health in under¬graduate dental students: fifth-year outcomes compared with first-year baseline results from five European dental schools. Eur J Dent Educ 2008; 12(2):61–8.
8.Polychronopoulou A, Divaris K. Dental students’ per¬ceived sources of stress: a multi-country study. J Dent Educ 2009; 73(5):631–9.
9.Goldstein M.B. Sources of stress and interpersonal support among first-year dental students. J. Dent. Edu. 1979;43(12):625–629.
10.Garbee W.H., Jr., Zucker S.B., Selby G.R. Perceived sources of stress among dental students. J. Am. Dent. Assoc. 1980;100(6):853–857.
11.Naidu RS, Adams JS, Simeon D, Persad S. Sources of stress and psychological disturbance among dental students in the West Indies. J Dent Educ 2002;66(9):1021–30.
Article citation:-
Preetinder Singh, Chandni Singla,Aditi priyamvara. The appraisal of perceived sources of stress and stress levels among dental students: A questionnaire survey. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 November 36(36): 1915-1918. Available at www.jpbms.info.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Source of support: Nil
Copyright © 2013 Preetinder Singh, Chandni Singla, Aditi priyamvara. This is an Open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Sakthibalan M1*,Sawadkar MS2,Asmathulla S3,Ivan EA4,Muthu G5
Affiliation:-
1Post Graduate,2Head of the Department, Department of Pharmacology, Sri Manakula Vinayagar Medical College And Hospital(SMVMCH), Pondicherry University, Pondicherry, India
3Associate Professor,5Assistant Professor, Department of Biochemistry,4Associate Professor, Department of Pathology, Sri Manakula Vinayagar Medical College And Hospital(SMVMCH), Pondicherry University, Pondicherry, India
Author’s contributions- All the authors contributed equally to this paper
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Pharmacology, Sri Manakula Vinayagar Medical College And Hospital(SMVMCH), Pondicherry University, Pondicherry, India.
Corresponding author:-
Dr. MurugesanSakthibalan.
Post Graduate, Department of Pharmacology,
Sri Manakula Vinayagar Medical College and Hospital, Madagadipet, Pondicherry, India – 605107
Ph No: 9443627722/98843591097/0413-2643000
Fax : 0413-26433014.
Abstract:
Background: The anthracycline antibiotic, Doxorubicin is effective in the treatment of a broad range of haematogenous and solid human malignancies. Its use is limited by its dose-dependent side effects like irreversible degenerative cardiomyopathy and congestive heart failure. The efficacy of doxorubicin against malignancies has prompted us to find treatments that reduce or prevent its cardiac side effects. Objective: To compare the effect of N-Acetylcysteine, Vitamin C and Enalapril given in different combinations to prevent doxorubicin induced cardio toxicity and oxidative stress in adult Wistar rats.
Methodology: The adult male wistar rats selected for the experiment are divided into 6 groups with 6 rats in each group. The rats in the control group and toxic control were administered sterile water and Doxorubicin (15 mg/kg stat dose i.p) respectively on day 5.Then N-Acetylcysteine, Enalapril and Vitamin c were administered per orally for 7 days in different combinations. On day 7 rat blood was collected for estimation of cardiac and oxidative stress markers. The rats were sacrificed and the cardiac tissue was sent for histopathological examination.
Statistical Analysis: Student unpaired‘t’ test and one-way ANOVA followed by Bonferroni test were applied.
Result and Conclusion: The triple drug combination of N-Acetylcysteine, Enalapril and Vitamin C can be used as an effective treatment along with Doxorubicin to limit its free radical mediated cardiotoxicity.
Key words: Doxorubicin; cardio toxicity; N-Acetylcysteine; Enalapril; Vitamin C.
Article citation:-
Sakthibalan M, Sawadkar MS, Asmathulla S, Ivan EA, Muthu G. Study of cardio protective effect of N-Acetylcysteine, Vitamin C and Enalapril given in combination to prevent doxorubicin induced cardio toxicity in Wistar rats. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 November 36(36): 1902-1908. Available at www.jpbms.info.
REFERENCES
1.Olson RD, Mushlin P. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 1990;4:3076–3086.
2.Shan K, LincoffAM, Young JB. Anthracycline-induced cardiotoxicity.Ann Intern Med. 1996;125:47–58.
3.Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900–905.
4.Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev.
2004;56:185–229.
5.Olson RD, Boerth RC, Gerber J, Nies AS. Mechanism of adriamycincardiotoxicity: evidence for oxidative stress. Life Sci. 1981;29:1393.
6.Billingham ME, Mason JW, Bristow MR, Daniels JR: Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treat Rep, 1978, 62, 865–872.
7.DoroshowJH ,Locker GY, Ifrim I, and Myers CE. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine.J Clin Invest. 1981 October; 68(4): 1053–1064.
8.Dodd s, Dean o,Copolov DL,Malhi GS,Berk M. N-acetylcysteine for antioxidant therapy:pharmacology and clinical utility.Expert Opinion on Biological Therapy, December 2008,
Vol. 8, No. 12 : Pages 1955-1962.
9.Hiona A, Lee AS, Nagendran J, Xie X, Connolly AJ, Robbins RC, Wu JC. Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via
preservation of mitochondrial function. J ThoracCardiovasc Surg.2011 Aug;142(2):396-403.
10.al-Shabanah O, Mansour M, el-Kashef H, al-Bekairi A. Captopril ameliorates myocardial and hematological toxicities induced by adriamycin.BiochemMolBiol Int. 1998
Jun;45(2):419-27.
11.Shi Y, Moon M, Dawood S, McManus B, Liu PP. Mechanisms and management of doxorubicin cardiotoxicity.Herz. 2011 Jun;36(4):296-305.
12.Abd El-Aziz MA, Othman AI, Amer M, El-Missiry MA. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced
acute cardiac and hepatic toxicity in rats. Journal of Applied Toxicology.Volume 21, Issue 6,pages 469–473.
13.Ivanovskio,SzumilakD,KhoaTN,RuellanN,PhanO,LacourB,LatschaBD,Drueke TB and Massy ZA. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic
apolipoprotein E knockout mice.Kidney International (2005) 67, 2288–2294.
14.Pathan RA, Singh BK, Pillai KK, and DubeyK.Naproxen aggravates doxorubicin-induced cardiomyopathy in rats.Indian J Pharmacol.2010 February; 42(1): 44–49.
15.Burtis CA, Ashwood ER, Border B, Tietz NW.TietzFundamentals of clinical chemistry.5th ed.Philadelphia.W.B.Saunders; 2001.
16.German society for clinical chemistry: Recommendations of the Enzyme Commision.J.Clin.Chem.Clin.Biochem.15:255(1997).
17.Anderson ME. Enzymatic and chemical methods for the determination of glutathione. In: Dolphin D, editor. Glutathione.1st vol. New York: John Wiley and Sons; 1983. p. 340–65.
18.Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem.1979; 95: 351-8.
19.Santos RV, Batista ML Jr, Caperuto EC, Costa Rosa LF. Chronic supplementation ofcreatine and vitamins C and E increases survival and improves biochemical parameters after
Doxorubicin treatment in rats. ClinExpPharmacol Physiol. 2007 Dec;34(12):1294-9.
20.Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, O'ConnorOA. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs.Cancer Res. 2008
Oct 1;68(19):8031-8.
21.Ozaslan M, Karagoz ID, Kilic IH and Guldur ME.Ehrlich ascites carcinoma. African Journal of Biotechnology Vol. 10(13), pp. 2375-2378.
22.Cornett PA, DeaTO.Current Medical Diagnosis & Treatment.50th ed.New York: McGraw Hill;2011.page 1592-93.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Source of support: Nil
Copyright © 2013. Mahajan Sakthibalan M, Sawadkar MS, Asmathulla S, Ivan EA, Muthu G. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Sakthibalan M1*, Nileshraj G1, Sawadkar MS2, Shanmugam M3
Affiliation:-
1Post Graduate,2Head of the Department, Department of Pharmacology, Sri Manakula Vinayagar Medical College and Hospital (SMVMCH), Pondicherry University, Pondicherry, India
3Head of the Department, Department of General Medicine, Sri Manakula Vinayagar Medical College and Hospital (SMVMCH), Pondicherry University, Pondicherry, India
Author’s contributions- All the authors contributed equally to this paper
The name of the department(s) and institution(s) to which the work should be attributed:
Sri Manakula Vinayagar Medical College and Hospital (SMVMCH), Pondicherry University, Pondicherry, India
Corresponding author:-
Dr. MurugesanSakthibalan.
Post Graduate, Department of Pharmacology,
Sri Manakula Vinayagar Medical College and Hospital, Madagadipet, Pondicherry, India – 605107
Ph No: 9443627722/98843591097/0413-2643000
Fax : 0413-26433014.
Abstract:
Background: Elevated Blood pressure is an important modifiable risk factor for cardiovascular diseases.The prescribing pattern of drugs used for treating hypertension changes over time in response to changes in recommended guidelines and innovations in drug formulations. Therefore it is necessary to find out the recent trends in prescribing anti-hypertensive medications by medical practitioners in upcoming medical practice.
Aims & objectives: To evaluate the recent trends in prescribing anti-hypertensive drugs, the different combinations being prescribed and the commonly prescribed dosage of individual drugs. Methodology: This study was carried out for a 3 months’ time period. The patients selected were in the age group of 25 to 90 years, diagnosed to have mild to severe systemic hypertension and on treatment, who were attending the OPD of General Medicine, without any co morbid conditions.
Result & Conclusion: The most common anti-hypertensive agents used were; CA channel blockers (76%) followed by β blockers (29.8%),AR blockers (19.9%) & ACE inhibitors (19.3%). Of the respondents 50.29% were receiving at least 2 anti-hypertensive agents. Most common agents used in combination were CA channel blockers + β blockers (40.96%) followed by AR blockers + CA channel blockers (22.89%) & ACE inhibitors + CA blockers (19.27%). The usage of two or more anti-hypertensive agents in combination has increased in the recent years, for better control of blood pressure. Though the usage of AR blockers and ACE inhibitors have increased, the CA channel blockers and β blockers tops the list in the most commonly prescribed anti-hypertensive agents.
Key words: Anti-hypertensive; Trends; CA channel blockers; β blockers; AR blockers; ACE inhibitors.
REFERENCES
1.Campbell NR, Brant R, Johansen H, Walker RL, Wielgosz A, Onysko J et al. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. Hypertension. 2009 Feb;53(2):128-34.
2.World Health Organization - The world health report 2002 –reducing risks, promoting healthy life. Geneva, Switzerland.
3.Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet. 2003 Nov 8; 362(9395):1527-35.
4.Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomized drug trials n their epidemiological context. Lancet. 1990 Apr 7;335(8693):827-38.
5.Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension. 2003 Dec;42(6):1206-52.
6.Lewington S, Clarke R, Qizibash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13.
7.Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996 May 22-29;275(20):1557-62.
8.Sipahi I, Tuzcu EM, Schoenhagen P, Wolski KE, Nicholls SJ, Balog C et al. Effects of normal, pre-hypertensive and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am CollCardiol. 2006 Aug 15;48(4):833-8.
9.Daniel AC, Veiga EV. Factors that interfere the medication compliance in hypertensive patients. Einstein (Sao Paulo). 2013 Sep;11(3):331-7.
10.Chan WK, Chung TS, Lau BS, Law HT, Yeung AK, Wong Ch. Hongkong Primary Care Foundation. Management of hypertension by private doctors in Hong Kong. Hong Kong Med J. 2006 Apr;12(2):115-8.
11.WHO Collaborating Centre for Drug Statistics Methodology. Complete ATC index 2012.Oslo, NO. Norwegian Instituite of Public Health. 2012.
12.Abaci A, Kozan O, Oguz A, Sahin M, Deger N, Senocak H et al. Prescribing pattern of antihypertensive drugs in primary care units in Turkey: results from the TURKSAHA study. Eur J ClinPharmacol. 2007 Apr;63(4):397-402.
13.Mohan V, Shanthirani S, Deepa R, Premalatha G, Sastry NG, Saroja R. Chennai Urban Population Study (CUPS No. 4). Intra-urban differences in the prevalence of the metabolic syndrome in southern India. Diabet Med. 2001 Apr;18(4):280-7.
14.Tiwari H, Kumar A, Kulkarni SK. Prescription monitoring of anti-hypertensive drug utilization at the Punjab University Health Centre in India. Singapore Med J. 2004 Mar;45(3):117-20.
Article citation:-
Sakthibalan M,Nileshraj G,Sawadkar MS,Shanmugam M. Recent trends in prescribing anti-hypertensives in a tertiarycare hospital. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 November 36(36): 1866-1870. Available at www.jpbms.info.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Source of support: Nil
Copyright © 2013. Sakthibalan M, Nileshraj G, Sawadkar MS, Shanmugam M.This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article
Rumana Farooq Mir1,*,Varsha.A.Singh2, Shinu P3
Affiliation:-
1Postgraduate student, 2Professor and Head, 3Assistant Professor, Department of Microbiology, Maharishi Markandeshwar University of Medical Sciences, Mullana, Ambala, Haryana, India-133207
Author’s contributions- All the authors contributed equally to this paper
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Microbiology, Maharishi Markandeshwar University of Medical Sciences, Mullana, Ambala, Haryana, India-133207
Corresponding author:-
Dr. Rumana Farooq Mir.
Postgraduate student,
Department of Microbiology.
Email id: rumanaishaq@gmail.com.
Mobile no: +91-7206098787.
Abstract:
Background: In spite of an effort in hospital infection control measures, health care associated infections are associated with considerable morbidity and mortality adding additional health care expenditure which leads to an economic crisis. Bacterial contamination in operating theatre and specialized care units contribute to nosocomial infections. The problem is further complicated with the emergence of multidrug resistant microorganism in the hospital environment which are difficult to treat.
Aim: Three year retrospective study was carried out to assess the bacterial contamination of operation theatres at MMIMSR hospital, Mullana. Ambala and to evaluate the effect of various seasons on the bacterial load.
Results: Of the 967 samples examined, 725 (70%) yielded positive bacterial growth. The distribution of bacterial pathogens isolated were Staphylococcus aureus 32.5% (n=236), Coagulase-negative Staphylococci (CoNS) accounted for 28% (n=203), followed by Pseudomonas aeruginosa 24% (n=174) and Escherichia coli 15.5% (n=112). The degree of bacterial contamination showed that Staphylococcus aureus predominated in all operation theatres sampled, with varied frequency of occurrence of other bacteria pathogens. Antibiotic susceptibility pattern of bacterial pathogens showed relative sensitivity to the drugs, particularly with cotrimoxazole, ampicillin, gentamycin and amiplicox.
Conclusion: High level of bacterial contamination with equipments indicates the needs for periodic microbiological surveillance aimed at early detection of bacterial contamination level and subsequent control on healthcare-associated infections.
Key words: Surgical site infections; Bacterial contamination; Fumigation.
Article citation:-
Rumana Farooq Mir,Varsha.A.Singh,Shinu P. Pre and post fumigation bacteriological profile of various operation theatres in MMIMSR- A three year retrospective study.. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 November 36(36): 1887-1891. Available at www.jpbms.info.
REFERENCES
1.Lilani SP, Jangale N, Chowdhary A, Daver GB. Surgical site infection in clean and clean-contaminated cases. Indian J Medical Microbiol 2005; 23(4):249-52.
2.Singh K, Dar FA, Kishor K. Bacterial contamination in operating theatres of district hospital budgam in Kashmir division. IJMHS 2013; 3(2): 62 -3.
3.Javed I, Hafeez, R, Zubair M, Anwar MS, Husnain S, Surveillance of operation theatres and ICUs of a tertiary hospital Lahore Biomedica 2008; 24: 99-102.
4.Emmerson MA. A microbiologist’s view of factor contributing to infection. New horizons (Baltmore, Md) 1998, 6(2): S3-10.
5.Mora R. Assessment of Thermal Comfort during Surgical Operations. ASHRAE Winter Meeting Program (Atlanta, GA) 2001; 27-31.
6. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin. Microbiol. Rev. 1993; 6(4):428-42.
7.Pasquarella C, Masia MD, Nnanga N, Sansebastiano GE, Savino A, Signorelli C, Veronesi L. Microbial air monitoring in operating theatre: active and passive samplings. Ann Ig. 2004; 16(1-2):375-86.
8.Khan MA, Ansari MN, Bano S. Post operative wound infection. Ind J Surg. 1985; 48:383-86.
9.Rao AS, Harsha M. Postoperative wound infections. J Indian MA1975; 64(4): 90-3.
10.Mangram AJ, Oran TC, Peanon ML. Guidelines for Prevention of SSI. Infection Control and Hospital Epidemiology 1999; 20(4):247-78.
11.Mawalla B, Mshana SE, Chalya1 PL, Imirzalioglu C, Mahalu W. Predictors of surgical site infections among patients undergoing major surgery at Bugando Medical Centre in Northwestern Tanzania. BMC Surgery 2011;11:21. doi:10.1186/1471-2482-11-21.
12.Nichols RL. Surgical Wound Infection. Am J Med 1991; 91:545-635.
13.Kotisso B, Assefa A. Surgical Wound Infections in a Teaching Hospital in Ethiopia. East Afr Med J 1998; 75(7): 402-5.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Source of support: Nil
Research article
Darlene Sredl*
Affiliation:-
Darlene Sredl, Ph.D., R.N.
Teaching professor, College of Nursing, University of Missouri-St Louis, One University Boulevard St. Louis, MO 63121-4400.
Corresponding author:-
Darlene Sredl, Ph.D., R.N.
Teaching professor, College of Nursing, University of Missouri-St Louis, One University Boulevard St. Louis, MO 63121-4400.
Core idea:
The paradigm is shifting! Contemporary research emphasis is on multidisciplinary modes of acquiring data. Even the emphasis of JPBMS is ‘Research across boundaries’ publishing multi-dimensional research venues. This article explores a new research methodology (Amalgamethodology) which was developed originally as a suggested research methodology unique to nursing. However, in practice, it has become clear that this methodology is well-suited to other scientific research endeavors also, particularly pharmacology.
Abstract:
Pharmacologic clinical trial research could yield far richer data by combining quantitative with qualitative methods, a process known as Amalgamethodology.
Key words: Amalgamethodology; Adaptive trial design; Pharmacodynamic Physiologically-based Pharmacodynamics (PBKP); Clinical trials Quantitative method; Qualitative method; Profile Analysis.
REFERENCES
1.Frohlich E. Clinical Pharmacology of Calcium Antagonists; Satellite Symposium on Calcium Antagonists. 7th Scientific Meeting of the Inter-American Society of Hypertension. Buenos Aires, Argentina: Hypertension II [Suppl I]: I-222-I224, 1988); 1987.
2.Sredl D. Amalgamethodology: A research methodology unique to nursing fostering critical thinking implications for education and practice. Journal of Applied Medical Sciences. 2013;2(1):61-73.
3.Greene JC, Caracelli, V.J. Graham, W.F. Toward a conceptual framework for mixed-methods evaluation designs. Education Evaluation Policy Analysis. 1989;11(3):255-274.
4.Macaluso M, Krams, M., & Preskorn, S. . Psycopharmacology Phase I Trials: From Traditional to Newer Approaches. Part II. Journal of Psychiatric Practice. 2011;17(4):277-284.
5.Sredl D. Evidence-Based Nursing Practice (EBNP): A Crystalized Synthesis of Apperceptions, Beliefs, and Efforts toward EBNP Implementation among Contemporary Nurse Executives in the United States of America St. Louis: College of Nursing, University of Missouri @ St. Louis; 2005.
6.Davison ML. Addendum to "Multidimensional scaling and factor models of test and item responses.": Department of Educational Psychology, University of Minnesota;1996.
7.Davison ML, Gasser M, Ding S. Identifying major profile patterns in a population: An exploratory study of WAIS and GATB patterns. Psychological Assessment. 1996;8:26 - 31.
8.Ding CS. Profile analysis: Multidimensional scaling approach. Practical Assessment, Research, and Evaluation 7(16) 2001; http://ericae.net/pare/Articles.htm, 2001.
9.Ding CS. Multidimensional Scaling Approach. Practical Assessment Research and Evaluation. 2001;7(16).
10.Davidson ML, Gasser, M., & Ding, C. Identifying major profile patterns in a population: An exploratory study of WAIS and GATB patterns. Psychological Assessment. 1996;8:26-31.
Sredl, D. Amalgamethodology: Building the Educational Evidence-Base for a Research Design Unique to the Science of Nursing. 11th Annual Nurse Educator Institute. North Arkansas Partnership for Health Education. Branson, MO March 15-15, 2011.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Source of support: Nil
Article citation:-
Darlene Sredl. Pharmacologic implications of utilizing amalgamethodology as adaptive trial design in clinical trial research methodology. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 November 35(35): 1860-1865. Available at www.jpbms.info.
Copyright © 2013 Darlene Sredl. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.